Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus

被引:11
作者
Tsai, Yi-Giien [1 ,2 ,3 ,4 ]
Liao, Pei-Fen [3 ,5 ]
Hsiao, Kai-Hung [6 ]
Wu, Hung-Ming [7 ]
Lin, Ching-Yuang [8 ]
Yang, Kuender D. [9 ,10 ]
机构
[1] Changhua Christian Childrens Hosp, Dept Pediat, Changhua, Taiwan
[2] Kaohsiung Med Univ, Sch Med, Kaohsiung 807, Kaohsiung, Taiwan
[3] Chung Shan Med Univ, Sch Med, Taichung, Taiwan
[4] Natl Chung Hsing Univ, Coll Med, Dept Postbaccalaureate Med, Taichung, Taiwan
[5] Chung Shan Med Univ Hosp, Dept Pediat, Div Allergy Asthma & Rheumatol, Taichung, Taiwan
[6] Changhua Christian Hosp, Dept Allergy Immunol & Rheumatol, Changhua, Taiwan
[7] Changhua Christian Hosp, Dept Neurol, Changhua, Taiwan
[8] China Med Univ Hosp, Childrens Hosp, Div Pediat Nephrol, Taichung, Taiwan
[9] MacKay Mem Hosp, Dept Pathol, New Taipei City, Taiwan
[10] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Taipei, Taiwan
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
systemic lupus erythematosus; lupus nephritis; regulatory T cells; interleukin-2; B regulatory cells; LOW-DOSE IL-2; B-CELLS; DISEASE-ACTIVITY; CD4(+); ACTIVATION; FOXP3; DIFFERENTIATION; SUPPRESSION; ASSOCIATION; CAPACITY;
D O I
10.3389/fimmu.2023.1230264
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Systemic lupus erythematosus (SLE) is a heterogeneous multisystem inflammatory disease with wide variability in clinical manifestations. Natural arising CD4+ regulatory T cells (Tregs) play a critical role in maintaining peripheral tolerance by suppressing inflammation and preventing autoimmune responses in SLE. Additionally, CD8+ regulatory T cells, type 1 regulatory T cells (Tr1), and B regulatory cells also have a less well-defined role in the pathogenesis of SLE. Elucidation of the roles of various Treg subsets dedicated to immune homeostasis will provide a novel therapeutic approach that governs immune tolerance for the remission of active lupus. Diminished interleukin (IL)-2 production is associated with a depleted Treg cell population, and its reversibility by IL-2 therapy provides important reasons for the treatment of lupus. This review focuses on the pathogenesis and new therapeutics of human Treg subsets and low-dose IL-2 therapy in clinical benefits with SLE.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Novel therapeutics for systemic lupus erythematosus
    Wiesendanger, Margrit
    Stanevsky, Anfisa
    Kovsky, Susan
    Diamond, Betty
    CURRENT OPINION IN RHEUMATOLOGY, 2006, 18 (03) : 227 - 235
  • [22] T Helper 2-Associated Immunity in the Pathogenesis of Systemic Lupus Erythematosus
    Ko, Haeun
    Kim, Chan Johng
    Im, Sin-Hyeog
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [23] Regulatory T cells in systemic lupus erythematosus
    Ohl, Kim
    Tenbrock, Klaus
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2015, 45 (02) : 344 - 355
  • [24] Interleukin 21 Correlates with T Cell and B Cell Subset Alterations in Systemic Lupus Erythematosus
    Terrier, Benjamin
    Costedoat-Chalumeau, Nathalie
    Garrido, Marlene
    Geri, Guillaume
    Rosenzwajg, Michelle
    Musset, Lucile
    Klatzmann, David
    Saadoun, David
    Cacoub, Patrice
    JOURNAL OF RHEUMATOLOGY, 2012, 39 (09) : 1819 - 1828
  • [25] Regulatory T cells and systemic lupus erythematosus
    Parietti, Veronique
    Chifflot, Helene
    Muller, Sylviane
    Monneaux, Fanny
    AUTOIMMUNITY, PT D: AUTOIMMUNE DISEASE, ANNUS MIRABILIS, 2007, 1108 : 64 - 75
  • [26] Aberrant T cell subsets and cytokines expression profile in systemic lupus erythematosus
    Zhou, Haiyan
    Hu, Bailong
    Huang, Niwen
    Mo, Xiangang
    Li, Wei
    Zhang, Bei
    Wei, Bo
    Gao, Mingzhu
    Wang, Yiming
    Liu, Xingde
    Liao, Joshua
    CLINICAL RHEUMATOLOGY, 2018, 37 (09) : 2405 - 2413
  • [27] Conversion of T Follicular Helper Cells to T Follicular Regulatory Cells by Interleukin-2 Through Transcriptional Regulation in Systemic Lupus Erythematosus
    Hao, He
    Nakayamada, Shingo
    Yamagata, Kaoru
    Ohkubo, Naoaki
    Iwata, Shigeru
    Inoue, Yoshino
    Zhang, Mingzeng
    Zhang, Tong
    Kanda Satoh, Yurie
    Shan, Yu
    Otsuka, Takashi
    Tanaka, Yoshiya
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 (01) : 132 - 142
  • [28] Cryptotanshinone ameliorates the pathogenesis of systemic lupus erythematosus by blocking T cell proliferation
    Du, Yu
    Du, Lijun
    He, Zhixing
    Zhou, Jia
    Wen, Chengping
    Zhang, Yun
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 74
  • [29] Aberrant expansion of follicular helper T cell subsets in patients with systemic lupus erythematosus
    Jin, Xin
    Chen, Jia
    Wu, Jian
    Lu, Ying
    Li, Baohua
    Fu, Wenning
    Wang, Wei
    Cui, Dawei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [30] Identification of regulatory T Cells in systemic lupus erythematosus
    Gerli, Roberto
    Nocentini, Giuseppe
    Alunno, Alessia
    Bocci, Elena Bartoloni
    Bianchini, Rodolfo
    Bistoni, Onelia
    Riccardi, Carlo
    AUTOIMMUNITY REVIEWS, 2009, 8 (05) : 426 - 430